Tenaya Therapeutics (TNYA) Fundamentals 2026 — Revenue Analysis | SniperIQ
Tenaya Therapeutics (TNYA) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tenaya Therapeutics's market cap?
Tenaya Therapeutics (TNYA) has a market capitalization of approximately
What is Tenaya Therapeutics's P/E ratio?
Tenaya Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tenaya Therapeutics?
Tenaya Therapeutics runs a net profit margin of -36891.1%, a gross margin of 144.9%, and an operating margin of -38159.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Tenaya Therapeutics pay a dividend?
Tenaya Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Tenaya Therapeutics financially healthy?
Tenaya Therapeutics carries a debt-to-equity ratio of 0.10x and a current ratio of 5.75x, with a market beta of 2.84. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tenaya Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tenaya Therapeutics (TNYA) the key facts are: market cap
Track Tenaya Therapeutics's full fundamentals live
Get Tenaya Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.